相关实验视频
Updated: Jun 13, 2025

07:59
Functional Characterization of Endogenously Expressed Human RYR1 Variants
Published on: June 9, 2021
2.5K
对于心力衰竭和心律失常性疾病中的二型氨酸受体泄漏的结构基础
Marco C Miotto1,2, Steven Reiken3,4, Anetta Wronska3,4
1Department of Physiology and Cellular Biophysics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA. mm5642@cumc.columbia.edu.
Nature communications
|September 15, 2024
概括
心力衰竭涉及异常的心脏瑞诺丁受体2通道,导致泄漏. 药物稳定这些通道,改善心脏功能,并通过关闭泄漏的通道来预防心律失常.
科学领域:
- 心血管生物学 心血管生物学
- 分子心脏病学分子心脏病学
- 结构生物学 结构生物学
背景情况:
- 心力衰竭是导致死亡的首要原因,与心脏里亚诺丁受体2 (RyR2) 通道异常有关.
- RyR2 功能障碍涉及过酸化,氧化和calstabin-2 枯竭,导致腹性泄漏.
- 基因 RyR2 突变也会导致泄漏,心律失常和心脏突然死亡.
研究的目的:
- 阐明 RyR2 功能障碍在心力衰竭和心脏突然死亡中的结构基础.
- 研究Rycal药物调节RyR2通道活性的机制.
主要方法:
- 低温电子显微镜 (cryo-EM) 用于确定RyR2变体的结构.
- 结构分析侧重于与心力衰竭和遗传性突发心脏病死亡相关的RyR2通道.
主要成果:
- 化EM结构显示了RyR2变体处于"初始化状态",在封闭和开放之间平衡.
- 瑞卡尔药物结合将RyR2通道从原始状态转移到封闭的形状.
- 这种转变减少了泄漏,增强了心脏收缩性,并减轻了心律失常.
结论:
- RyR2通道的启动状态被认为是心力衰竭中心律失常的关键机制.
- 通过稳定RyR2通道并减少泄漏,Rycal药物提供了一个潜在的治疗策略.
- 结构性见解为开发针对心律失常和心力衰竭的向治疗提供了基础.
相关概念视频
Mechanism of Cardiac Arrhythmias
900
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
900
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
719
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
719
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
Electrophysiology of Normal Cardiac Rhythm
2.3K
The normal cardiac rhythm is a synchronized electrical activity that facilitates the regular and coordinated contraction of the heart muscle. This process is essential for efficient blood circulation throughout the body. The fundamental elements involved in establishing and maintaining this rhythm include the unique electrical properties of cardiac muscle cells, the sinoatrial (SA) node's pacemaker function, the specialized conducting system, and the ionic mechanisms underlying each phase...
2.3K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
933
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
933
Cardiac Action Potential
1.1K
Cardiac action potentials are essential for proper heart function, enabling the rhythmic contractions needed for adequate blood circulation. Nodal cells and Purkinje fibers, specialized for electrical conduction, generate these action potentials.
The cardiac action potential process involves a series of phases characterized by the movement of ions across the cardiac cell membranes, leading to the depolarization and repolarization of the cardiac myocytes.
Ionic Basis of Cardiac Action Potentials
The cardiac action potential process involves a series of phases characterized by the movement of ions across the cardiac cell membranes, leading to the depolarization and repolarization of the cardiac myocytes.
Ionic Basis of Cardiac Action Potentials
1.1K

